Title: Original Article HighDose Atorvastatin after Stroke or Transient Ischemic Attack
1Original Article High-Dose Atorvastatin after
Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators
N Engl J Med Volume 355(6)549-559 August 10, 2006
2Study Overview
- In this five-year placebo-controlled trial
involving patients who had a recent stroke or
transient ischemic attack and baseline
low-density lipoprotein cholesterol levels of 100
to 190 mg per deciliter (3 to 5 mmol per liter),
atorvastatin (80 mg daily) resulted in an
absolute reduction in nonfatal or fatal stroke of
2.2 percent and of major cardiovascular events of
3.5 percent
3Screening, Enrollment, and Outcomes
The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators. N Engl
J Med 2006355549-559
4Baseline Characteristics of the Patients
The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators. N Engl
J Med 2006355549-559
5Estimates of the Hazard Ratio for the Primary and
Secondary Efficacy Outcome Measures
The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators. N Engl
J Med 2006355549-559
6Kaplan-Meier Curves for Stroke and TIA
The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators. N Engl
J Med 2006355549-559
7Kaplan-Meier Curves for Coronary and
Cardiovascular Events
The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators. N Engl
J Med 2006355549-559
8Incidence of Adverse Events and Elevated
Laboratory Values
The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators. N Engl
J Med 2006355549-559
9Conclusion
- In patients with recent stroke or TIA and without
known coronary heart disease, 80 mg of
atorvastatin per day reduced the overall
incidence of strokes and of cardiovascular
events, despite a small increase in the incidence
of hemorrhagic stroke